Akebia Therapeutics, Inc. (NASDAQ:AKBA) is set to issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.36. The company had revenue of $28.52 million for the quarter, compared to analyst estimates of $26.50 million. On average, analysts expect Akebia Therapeutics to post $-3.03 EPS for the current fiscal year and $-1.4 EPS for the next fiscal year.

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) opened at 17.63 on Tuesday. The firm has a 50-day moving average price of $18.14 and a 200-day moving average price of $15.01. Akebia Therapeutics, Inc. has a 52-week low of $7.16 and a 52-week high of $20.25. The stock’s market cap is $322.63 million.

AKBA has been the topic of several analyst reports. Zacks Investment Research upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Royal Bank Of Canada restated an “outperform” rating and set a $28.00 price objective on shares of Akebia Therapeutics in a report on Saturday, September 16th. Finally, HC Wainwright decreased their price objective on Akebia Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 10th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $22.00.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/31/akebia-therapeutics-inc-akba-scheduled-to-post-quarterly-earnings-on-tuesday.html.

In related news, SVP Michel Dahan sold 5,000 shares of Akebia Therapeutics stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $15.00, for a total value of $75,000.00. Following the transaction, the senior vice president now owns 102,224 shares in the company, valued at $1,533,360. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 12,586 shares of company stock worth $222,289 in the last quarter. 8.67% of the stock is owned by insiders.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.